Efficacy of Locoregional Treatment for Oligo-Drug-Resistant Lesions during First-Line Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma: A Single-Center Retrospective Study

2.

Llovet

JM

,

Ricci

S

,

Mazzaferro

V

,

Hilgard

P

,

Gane

E

,

Blanc

JF

, et al.

Sorafenib in advanced hepatocellular carcinoma

.

N Engl J Med

.

2008

;

359

(

4

):

378

–

90

.

3.

Kudo

M

,

Finn

RS

,

Qin

S

,

Han

KH

,

Ikeda

K

,

Piscaglia

F

, et al.

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

.

Lancet

.

2018

;

391

(

10126

):

1163

–

73

.

4.

Cheng

AL

,

Qin

S

,

Ikeda

M

,

Galle

PR

,

Ducreux

M

,

Kim

TY

, et al.

Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

.

J Hepatol

.

2022

;

76

(

4

):

862

–

73

.

5.

Abou-Alfa

GK

,

Lau

G

,

Kudo

M

,

Chan

SL

,

Kelley

RK

,

Furuse

J

, et al.

Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

.

NEJM Evid

.

2022

;

1

(

8

):

EVIDoa2100070

.

6.

Gordan

JD

,

Kennedy

EB

,

Abou-Alfa

GK

,

Beg

MS

,

Brower

ST

,

Gade

TP

, et al.

Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline

.

J Clin Oncol

.

2020

;

38

(

36

):

4317

–

45

.

7.

Bruix

J

,

Chan

SL

,

Galle

PR

,

Rimassa

L

,

Sangro

B

.

Systemic treatment of hepatocellular carcinoma: an EASL position paper

.

J Hepatol

.

2021

;

75

(

4

):

960

–

74

.

8.

Llovet

JM

,

Villanueva

A

,

Marrero

JA

,

Schwartz

M

,

Meyer

T

,

Galle

PR

, et al.

Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference

.

Hepatology

.

2021

;

73

(

Suppl 1

):

158

–

91

.

9.

Kudo

M

,

Kawamura

Y

,

Hasegawa

K

,

Tateishi

R

,

Kariyama

K

,

Shiina

S

, et al.

Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update

.

Liver Cancer

.

2021

;

10

(

3

):

181

–

223

.

10.

Llovet

JM

,

Castet

F

,

Heikenwalder

M

,

Maini

MK

,

Mazzaferro

V

,

Pinato

DJ

, et al.

Immunotherapies for hepatocellular carcinoma

.

Nat Rev Clin Oncol

.

2022

;

19

(

3

):

151

–

72

.

11.

Kudo

M

,

Aoki

T

,

Ueshima

K

,

Tsuchiya

K

,

Morita

M

,

Chishina

H

, et al.

Achievement of complete response and drug-free status by atezolizumab plus bevacizumab combined with or without curative conversion in patients with transarterial chemoembolization-unsuitable, intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study

.

Liver Cancer

.

2023

;

12

(

4

):

321

–

38

.

12.

Shimose

S

,

Iwamoto

H

,

Shirono

T

,

Tanaka

M

,

Niizeki

T

,

Kajiwara

M

, et al.

The impact of curative conversion therapy aimed at a cancer-free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab

.

Cancer Med

.

2023

;

12

(

11

):

12325

–

35

.

13.

Tomonari

T

,

Tani

J

,

Sato

Y

,

Tanaka

H

,

Tanaka

T

,

Taniguchi

T

, et al.

Clinical features and outcomes of conversion therapy in patients with unresectable hepatocellular carcinoma

.

Cancers

.

2023

;

15

(

21

):

5221

.

14.

Nakabori

T

,

Higashi

S

,

Abe

Y

,

Mukai

K

,

Ikawa

T

,

Konishi

K

, et al.

Safety and feasibility of combining on-demand selective locoregional treatment with first-line atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma

.

Curr Oncol

.

2024

;

31

(

3

):

1543

–

55

.

15.

Takayama

T

,

Hasegawa

K

,

Izumi

N

,

Kudo

M

,

Shimada

M

,

Yamanaka

N

, et al.

Surgery versus radiofrequency ablation for Small Hepatocellular Carcinoma: a randomized controlled trial (SURF Trial)

.

Liver Cancer

.

2022

;

11

(

3

):

209

–

18

.

16.

de Baère

T

,

Aupérin

A

,

Deschamps

F

,

Chevallier

P

,

Gaubert

Y

,

Boige

V

, et al.

Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases

.

Ann Oncol

.

2015

;

26

(

5

):

987

–

91

.

17.

Luke

JJ

,

Lemons

JM

,

Karrison

TG

,

Pitroda

SP

,

Melotek

JM

,

Zha

Y

, et al.

Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors

.

J Clin Oncol

.

2018

;

36

(

16

):

1611

–

8

.

18.

Heimbach

JK

,

Kulik

LM

,

Finn

RS

,

Sirlin

CB

,

Abecassis

MM

,

Roberts

LR

, et al.

AASLD guidelines for the treatment of hepatocellular carcinoma

.

Hepatology

.

2018

;

67

(

1

):

358

–

80

.

19.

Marrero

JA

,

Kulik

LM

,

Sirlin

CB

,

Zhu

AX

,

Finn

RS

,

Abecassis

MM

, et al.

Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases

.

Hepatology

.

2018

;

68

(

2

):

723

–

50

.

20.

European Association for the Study of the Liver

.

EASL clinical practice guidelines: management of hepatocellular carcinoma

.

J Hepatol

.

2018

;

69

(

1

):

182

–

236

.

21.

Bolondi

L

,

Burroughs

A

,

Dufour

JF

,

Galle

PR

,

Mazzaferro

V

,

Piscaglia

F

, et al.

Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions

.

Semin Liver Dis

.

2012

;

32

(

4

):

348

–

59

.

22.

Eisenhauer

EA

,

Therasse

P

,

Bogaerts

J

,

Schwartz

LH

,

Sargent

D

,

Ford

R

, et al.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

.

Eur J Cancer

.

2009

;

45

(

2

):

228

–

47

.

23.

Kudo

M

,

Ueshima

K

,

Ikeda

M

,

Torimura

T

,

Tanabe

N

,

Aikata

H

, et al.

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial

.

Gut

.

2020

;

69

(

8

):

1492

–

501

.

24.

Wang

F

,

Numata

K

,

Komiyama

S

,

Miwa

H

,

Sugimori

K

,

Ogushi

K

, et al.

Combination therapy with lenvatinib and radiofrequency ablation for patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and child-pugh class a liver function: a pilot study

.

Front Oncol

.

2022

;

12

:

843680

.

25.

Johnson

PJ

,

Berhane

S

,

Kagebayashi

C

,

Satomura

S

,

Teng

M

,

Reeves

HL

, et al.

Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade

.

J Clin Oncol

.

2015

;

33

(

6

):

550

–

8

.

26.

Hiraoka

A

,

Kumada

T

,

Tsuji

K

,

Takaguchi

K

,

Itobayashi

E

,

Kariyama

K

, et al.

Validation of modified ALBI grade for more detailed assessment of hepatic function in hepatocellular carcinoma patients: a multicenter analysis

.

Liver Cancer

.

2019

;

8

(

2

):

121

–

9

.

27.

Dindo

D

,

Demartines

N

,

Clavien

PA

.

Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey

.

Ann Surg

.

2004

;

240

(

2

):

205

–

13

.

28.

Kanda

Y

.

Investigation of the freely available easy-to-use software “EZR” for medical statistics

.

Bone Marrow Transpl

.

2013

;

48

(

3

):

452

–

8

.

29.

Nakabori

T

,

Ikawa

T

,

Kozumi

K

,

Urabe

M

,

Kai

Y

,

Takada

R

, et al.

Abscopal effect in a patient with advanced hepatocellular carcinoma upon resuming bevacizumab in combination with atezolizumab after radiotherapy

.

Clin J Gastroenterol

.

2024

;

17

(

6

):

1053

–

7

.

30.

Bozic

I

,

Antal

T

,

Ohtsuki

H

,

Carter

H

,

Kim

D

,

Chen

S

, et al.

Accumulation of driver and passenger mutations during tumor progression

.

Proc Natl Acad Sci USA

.

2010

;

107

(

43

):

18545

–

50

.

31.

Durrett

R

,

Foo

J

,

Leder

K

,

Mayberry

J

,

Michor

F

.

Intratumor heterogeneity in evolutionary models of tumor progression

.

Genetics

.

2011

;

188

(

2

):

461

–

77

.

32.

Uchi

R

,

Takahashi

Y

,

Niida

A

,

Shimamura

T

,

Hirata

H

,

Sugimachi

K

, et al.

Integrated multiregional analysis proposing a new model of colorectal cancer evolution

.

PLoS Genet

.

2016

;

12

(

2

):

e1005778

.

33.

Kissel

M

,

Martel-Lafay

I

,

Lequesne

J

,

Faivre

JC

,

Le Péchoux

C

,

Stefan

D

, et al.

Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer

.

BMC Cancer

.

2019

;

19

(

1

):

1237

.

34.

Damen

PJJ

,

Suijkerbuijk

KPM

,

Van Lindert

ASR

,

Eppinga

WSC

,

El Sharouni

SY

,

Verhoeff

JJC

.

Long-term local control and overall survival after radiotherapy in oligoprogressive patients during treatment with checkpoint inhibitors

.

Anticancer Res

.

2022

;

42

(

10

):

4795

–

804

.

35.

Kim

H

,

Venkatesulu

BP

,

McMillan

MT

,

Verma

V

,

Lin

SH

,

Chang

JY

, et al.

Local therapy for oligoprogressive disease: a systematic review of prospective trials

.

Int J Radiat Oncol Biol Phys

.

2022

;

114

(

4

):

676

–

83

.

36.

Ozluk

AA

,

Karateke

M

,

Sanli

UA

,

Karaca

B

.

Efficacy of local ablative therapies in patients with solid tumors treated with immune checkpoint inhibitors and oligoprogression: a single-center analysis

.

Melanoma Res

.

2023

;

33

(

5

):

417

–

21

.

37.

Maeda

M

,

Saeki

I

,

Sakaida

I

,

Aikata

H

,

Araki

Y

,

Ogawa

C

, et al.

Complications after radiofrequency ablation for hepatocellular carcinoma: a multicenter study involving 9,411 Japanese patients

.

Liver Cancer

.

2020

;

9

(

1

):

50

–

62

.

38.

Durand-Labrunie

J

,

Baumann

AS

,

Ayav

A

,

Laurent

V

,

Boleslawski

E

,

Cattan

S

, et al.

Curative irradiation treatment of hepatocellular carcinoma: a multicenter Phase 2 trial

.

Int J Radiat Oncol Biol Phys

.

2020

;

107

(

1

):

116

–

25

.

39.

Jang

WI

,

Bae

SH

,

Kim

MS

,

Han

CJ

,

Park

SC

,

Kim

SB

, et al.

A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: safety and efficacy

.

Cancer

.

2020

;

126

(

2

):

363

–

72

.

40.

Zhang

L

,

Xu

L

,

Wang

Y

,

Liu

X

,

Zhang

M

,

Li

W

.

Antitumor immunity augmented by combining radiofrequency ablation with anti-CTLA-4 therapy in a subcutaneous murine hepatoma model

.

J Vasc Interv Radiol

.

2020

;

31

(

7

):

1178

–

86

.

41.

Liao

C

,

Zhang

G

,

Huang

R

,

Zeng

L

,

Chen

B

,

Dai

H

, et al.

Inducing the abscopal effect in liver cancer treatment: the impact of microwave ablation power levels and PD-1 antibody therapy

.

Pharmaceuticals

.

2023

;

16

(

12

):

1672

.

42.

van den Bijgaart

RJE

,

Schuurmans

F

,

Fütterer

JJ

,

Verheij

M

,

Cornelissen

LAM

,

Adema

GJ

.

Immune modulation plus tumor ablation: adjuvants and antibodies to prime and boost anti-tumor immunity in situ

.

Front Immunol

.

2021

;

12

:

617365

.

43.

Duan

Y

,

Zhang

H

,

Tan

T

,

Ye

W

,

Yin

K

,

Yu

Y

, et al.

The immune response of hepatocellular carcinoma after locoregional and systemic therapies: the available combination option for immunotherapy

.

Biosci Trends

.

2024

;

17

(

6

):

427

–

44

.

44.

Singh

P

,

Toom

S

,

Avula

A

,

Kumar

V

,

Rahma

OE

.

The immune modulation effect of locoregional therapies and its potential synergy with immunotherapy in hepatocellular carcinoma

.

J Hepatocell Carcinoma

.

2020

;

7

:

11

–

7

.

45.

Terashima

T

,

Yamashita

T

,

Arai

K

,

Kawaguchi

K

,

Kitamura

K

,

Yamashita

T

, et al.

Beneficial effect of maintaining hepatic reserve during chemotherapy on the outcomes of patients with hepatocellular carcinoma

.

Liver Cancer

.

2017

;

6

(

3

):

236

–

49

.

46.

Ueshima

K

,

Nishida

N

,

Hagiwara

S

,

Aoki

T

,

Minami

T

,

Chishina

H

, et al.

Impact of baseline ALBI grade on the outcomes of hepatocellular carcinoma patients treated with lenvatinib: a multicenter study

.

Cancers

.

2019

;

11

(

7

):

952

.

47.

Chen

CT

,

Feng

YH

,

Yen

CJ

,

Chen

SC

,

Lin

YT

,

Lu

LC

, et al.

Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment

.

Hepatol Int

.

2022

;

16

(

5

):

1199

–

207

.

48.

Armstrong

S

,

Roy

T

,

Singh

B

,

Kulasekaran

M

,

Shaukat

F

,

Geng

X

, et al.

TKIs beyond immunotherapy predict improved survival in advanced HCC

.

J Cancer Res Clin Oncol

.

2023

;

149

(

6

):

2559

–

74

.

49.

Gettinger

S

,

Horn

L

,

Jackman

D

,

Spigel

D

,

Antonia

S

,

Hellmann

M

, et al.

Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study

.

J Clin Oncol

.

2018

;

36

(

17

):

1675

–

84

.

50.

Osa

A

,

Uenami

T

,

Koyama

S

,

Fujimoto

K

,

Okuzaki

D

,

Takimoto

T

, et al.

Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients

.

JCI Insight

.

2018

;

3

(

19

):

e59125

.